Renovaro to Acquire Predictive Oncology in All-Stock Transaction Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of long

Renovaro to Acquire Predictive Oncology in All-Stock Transaction

Acquisition provides access to critical resources encompassing a biobank

of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data

Data provides a critical pathway to progress AI using the high-speed

computing power provided through collaboration with Nebul

Combines Predictive Oncology's AI-driven multi-omic drug discovery

platform with Renovaro's AI Cube multi-omic artificial intelligence to advance both cancer diagnostics and early drug discovery

Planned test launch to assist physicians in individualizing cancer therapy

to improve treatment outcomes

Los Angeles - January 6, 2025 -

Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced

it has entered into a binding LOI to acquire Predictive Oncology (NASDAQ: POAI) in an all-stock transaction.

David Weinstein, Chief Executive Officer of Renovaro,

commented, "Renovaro is on a quest to offer cancer patients early diagnostic options, treatment protocols, and recurrence monitoring.

Predictive Oncology will enhance our capabilities by assisting oncologists with patient specific diagnostic and therapeutic clinical support

data. Predictive Oncology's proprietary AI/ML platform has been proven to predict tumor-drug response with 92% accuracy which, I

believe, will allow us to launch as a decision support platform for medical oncologists in 2025. As importantly, there are strong synergies

with Predictive's small molecule solid tumor drug-tumor response modeling capabilities and Renovaro's liquid biopsy approach

to early cancer detection and monitoring."

Raymond Vennare, Chief Executive Officer of Predictive

Oncology, added, "We recognize that by integrating Predictive Oncology's AI-driven drug discovery platform and vast biobank

of more than 150,000 patient tumor samples, 200,000 pathology slides and decades of longitudinal drug response data with Renovaro's

multi-disciplinary artificial intelligence, multi-omics and multi-modal data expertise, we are opening to door to diagnostic, therapeutic

and drug discovery possibilities that we otherwise would never have considered."

Short-Term Synergies

Predictive Oncology announced on November 13, 2024,

that the company's Board of Directors, working with a strategic advisor, had initiated a process to evaluate a broad range of strategic

alternatives intended to maximize shareholder value and issued an update on December 3, 2024, stating the Company was engaged in productive

discussions with multiple interested parties and looked forward to the timely completion of this process.

Renovaro will acquire 100% of Predictive Oncology

common shares through the issuance of Preferred stock.

About Predictive Oncology

Predictive Oncology is on the cutting edge of the

rapidly growing use of artificial intelligence and machine learning to expedite early biomarker and drug discovery and enable drug development

for the benefit of cancer patients worldwide. The company's proprietary AI/ML platform has been scientifically validated to predict

with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type

combinations for subsequent in-vitro testing. Together with the company's vast biobank of more than 150,000 assay-capable heterogenous

human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry's broadest AI-based drug

discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. Predictive Oncology is headquartered in Pittsburgh,

PA. https://predictive-oncology.com/

Renovaro https://renovarogroup.com/ aims

to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early

diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy

company and RenovaroCube.

Forward-Looking Statements

Statements in this press release that are not strictly

historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations

and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising.

All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology

such as "believes," "plans," "expects," "aims," "intends," "potential,"

or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties,

including as set forth in Renovaro's most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to

place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified

in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect

events or circumstances after the date hereof.

Executive Vice President

MZ Group - MZ North America

For media inquiries, please contact:

karen@renovarocube.com and STarsh@Renovarogroup.com